Work

Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps9603

Authors: Andrew Scott Brohl, Melissa Amber Burgess, Gino Kim In, Karam Khaddour, Peter M O'Neill, Sunil A. Reddy, Eric D. Whitman, James A. Bianco

Institutions: Moffitt Cancer Center, UPMC Hillman Cancer Center, USC Norris Comprehensive Cancer Center, Dana-Farber Cancer Institute, Stanford University, Atlantic Health System

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804996

FWCI:

Cites:

Cited by:

Related to: 10